Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Almost 200 years ago, benzamide was reported as polymorphic with two of its forms (II and III) found to be difficult to crystallise. In a recent study, it was shown that benzamide form I can easily convert into benzamide form III using mechanochemistry in the presence of nicotinamide. Here we show, experimentally and computationally, that this transformation is the result of a thermodynamic switch between these two polymorphic forms driven by the formation of solid solutions with small amounts of nicotinamide. The presence of nicotinamide in the crystallisation environment promotes the robust and exclusive crystallisation of the elusive form III. These results represent a promising route to the synthesis and utilisation of elusive polymorphs of pharmaceutical interest.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814557PMC
http://dx.doi.org/10.1038/s42004-021-00473-7DOI Listing

Publication Analysis

Top Keywords

benzamide form
12
form iii
12
polymorphic forms
8
presence nicotinamide
8
switching polymorph
4
polymorph stabilities
4
stabilities impurities
4
impurities thermodynamic
4
thermodynamic route
4
benzamide
4

Similar Publications

Approximately 1.5 million people worldwide suffer from chronic myeloid leukemia (CML). MicroRNAs (miRs) are important regulators of gene expression and offer an attractive option as biomarkers for cancer detection, diagnosis, and prognosis assessment in solid and liquid tumors.

View Article and Find Full Text PDF

Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease.

Clin Transl Med

August 2025

Tulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, Tulane University School of Medicine, Tulane University, New Orleans, Louisiana, USA.

Background: Alzheimer's disease (AD) is a growing healthcare crisis with limited effective therapies. This study aims to identify new candidate drugs that can be repurposed using key transcriptional regulators (DERs) in AD as therapeutic targets.

Methods: Multi-cohort single-nucleus RNA sequencing (snRNA-seq) data from the prefrontal cortex were analysed to identify DERs.

View Article and Find Full Text PDF

Background: Prostate cancer is a common and deadly cancer among men and has been the subject of many patients in its diagnosis and treatment. Imatinib, a tyrosine kinase inhibitor, can slow tumor formation by targeting c-KIT, an oncogenic receptor tyrosine kinase protein over-expressed in PCa cases. However, Imatinib has no effect on tr-KIT, a truncated form of c-KIT, which is over-expressed in PCa and is associated with neoplastic transformation.

View Article and Find Full Text PDF

Chronic myelogenous leukemia (CML) is a cancer of the white blood cells that results from uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The most common form of treatment for CML is imatinib, a tyrosine kinase inhibitor. Although imatinib is an effective treatment for CML and most patients treated with imatinib do attain some form of remission, imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually relapse.

View Article and Find Full Text PDF

A one-step synthetic strategy for directly converting benzamides into -formanilide derivatives has been developed using oxalic acid as a hydride source. This strategy involves the selective cleavage of the amide C-N bond through a reaction with sodium azide, generating a benzyl azide intermediate. This intermediate subsequently undergoes Curtius rearrangement to form an isocyanate species, which is then reduced by thermally decomposed oxalic acid, yielding the final -formylated product.

View Article and Find Full Text PDF